Alessandro Gozzetti, Paola Pacelli, Donatella Raspadori, Elena Bestoso, Dania Tocci, Anna Sicuranza, Monica Bocchia
{"title":"长期CR多发性骨髓瘤患者显示治愈或mgus样最小残留疾病模式的下一代流。","authors":"Alessandro Gozzetti, Paola Pacelli, Donatella Raspadori, Elena Bestoso, Dania Tocci, Anna Sicuranza, Monica Bocchia","doi":"10.2174/1574887117666220516145628","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In the era of novel agents, many multiple myeloma patients can achieve a complete remission, but most of them relapse, and minimal residual disease detection can play a crucial role. Next-generation flow (NGF) can detect monoclonal plasma cells with a sensitivity of 10<sup>-6</sup>. Little is known about long-term remission patients (> 2 years) and in particular, if more sensitive techniques such as NGF can still detect minimal disease in those patients.</p><p><strong>Objective: </strong>Aim of the study was to analyze patients with MM in response to NGF at > 2 years of sustained remission after several treatments.</p><p><strong>Methods: </strong>MRD was studied by NGF in bone marrow aspirates according to Euroflow Consortium indications.</p><p><strong>Results: </strong>62 patients with sustained CR at >2 years were studied, MRD+ status was detected at a threshold cut-off of 10<sup>-6</sup> in 32/62 (52%); 4/15 (27%) patients were MRD positive at >5 years of remission and they displayed a prevalence of normal vs abnormal monoclonal plasma cell immune-phenotype (MGUS-like).</p><p><strong>Conclusion: </strong>NGF is a powerful technique to detect MRD. Myeloma patients in prolonged sustained complete remission can show in high percentage an MRD negative status or MGUS like.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.\",\"authors\":\"Alessandro Gozzetti, Paola Pacelli, Donatella Raspadori, Elena Bestoso, Dania Tocci, Anna Sicuranza, Monica Bocchia\",\"doi\":\"10.2174/1574887117666220516145628\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In the era of novel agents, many multiple myeloma patients can achieve a complete remission, but most of them relapse, and minimal residual disease detection can play a crucial role. Next-generation flow (NGF) can detect monoclonal plasma cells with a sensitivity of 10<sup>-6</sup>. Little is known about long-term remission patients (> 2 years) and in particular, if more sensitive techniques such as NGF can still detect minimal disease in those patients.</p><p><strong>Objective: </strong>Aim of the study was to analyze patients with MM in response to NGF at > 2 years of sustained remission after several treatments.</p><p><strong>Methods: </strong>MRD was studied by NGF in bone marrow aspirates according to Euroflow Consortium indications.</p><p><strong>Results: </strong>62 patients with sustained CR at >2 years were studied, MRD+ status was detected at a threshold cut-off of 10<sup>-6</sup> in 32/62 (52%); 4/15 (27%) patients were MRD positive at >5 years of remission and they displayed a prevalence of normal vs abnormal monoclonal plasma cell immune-phenotype (MGUS-like).</p><p><strong>Conclusion: </strong>NGF is a powerful technique to detect MRD. Myeloma patients in prolonged sustained complete remission can show in high percentage an MRD negative status or MGUS like.</p>\",\"PeriodicalId\":21174,\"journal\":{\"name\":\"Reviews on recent clinical trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews on recent clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1574887117666220516145628\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574887117666220516145628","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.
Background: In the era of novel agents, many multiple myeloma patients can achieve a complete remission, but most of them relapse, and minimal residual disease detection can play a crucial role. Next-generation flow (NGF) can detect monoclonal plasma cells with a sensitivity of 10-6. Little is known about long-term remission patients (> 2 years) and in particular, if more sensitive techniques such as NGF can still detect minimal disease in those patients.
Objective: Aim of the study was to analyze patients with MM in response to NGF at > 2 years of sustained remission after several treatments.
Methods: MRD was studied by NGF in bone marrow aspirates according to Euroflow Consortium indications.
Results: 62 patients with sustained CR at >2 years were studied, MRD+ status was detected at a threshold cut-off of 10-6 in 32/62 (52%); 4/15 (27%) patients were MRD positive at >5 years of remission and they displayed a prevalence of normal vs abnormal monoclonal plasma cell immune-phenotype (MGUS-like).
Conclusion: NGF is a powerful technique to detect MRD. Myeloma patients in prolonged sustained complete remission can show in high percentage an MRD negative status or MGUS like.
期刊介绍:
Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.